WASHINGTON, June 24, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2024 on Tuesday, July 23, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading " ...

WASHINGTON, June 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr. Weidemanis will support the transition over the next three months and will retire from Danaher on September 30, 2024 after 13 years of service.  Ms. Sawyer Montgomery, currently Vice President and Gr ...

Danaher Corporation (DHR) is posed to gain from strength in the Life Sciences segment and accretive acquisitions.However, softness in the Biotechnology segment raises concerns for the company. Decreased demand in the bioprocessing business has been weighing on the performance of the segment. Given the company’s international exposure, forex woes are weighing on its top line.What’s Aiding DHR?Business Strength: Stable demand in the academic and applied markets and strong momentum in the genomics consumables ...

文章核心观点 - 公司正在加大对人工智能(AI)的投资,将其视为创新和生产力的驱动力 [1][2][4] - 公司任命了首席数据和人工智能官,以进一步推进公司的AI和数据战略,加速创新 [2][3] - 公司将在12月举办创新峰会,探讨AI在生物制药研发领域的潜在影响 [1][4] 公司概况 - 公司是一家全球性的科技和生命科学创新企业,致力于加速科技进步,改善人类健康 [5] - 公司拥有约63,000名员工,致力于提高诊断速度和准确性,缩短药物研发周期 [5] - 公司专注于科学卓越、创新和持续改进,为当下和未来的健康可持续发展做出贡献 [5] 人工智能战略 - 公司正通过内部能力建设、外部投资并购、与学术机构合作等方式加强AI能力 [4] - 新任命的首席数据和人工智能官拥有丰富的AI应用经验,将在公司AI战略中发挥关键作用 [2][3] - 公司将在12月的创新峰会上探讨AI在生物制药研发领域的潜在影响 [1][4]

A month has gone by since the last earnings report for Danaher (DHR) . Shares have added about 6.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Danaher due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Danaher Q1 Earnings Beat, Biotechnology Sales Dip Y/YDanaher’s ...

Danaher Corporation (DHR) has been benefiting from strength in its Life Sciences segment, driven by stable demand in the academic and applied markets, and strong momentum in the genomics consumables business. The company has been witnessing positive responses from its new products like IDBS' Polar Insight and Molecular Devices' CellXpress.ai, which help accelerate the drug discovery process and bring new therapies to market faster. Also, in the Diagnostics unit, new solutions like Beckman Coulter's DxI 9000 ...

Sirius XM Holdings Inc. (SIRI) BofA Securities 2024 Health Care Conference Call May 14, 2024 1:40 PM ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Participants Michael Ryskin - Bank of America Michael Ryskin Everyone will kick things off for our next session. My name is Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics teams and I'm thrilled to host Danaher and I'm joined by Rainer Blair, CEO. Rainer, thanks so much for coming. Rainer B ...

业绩总结 - 公司第一季度营收表现强劲，仅较高个位数的指导下降4%[4] - 第一季度营运利润率达到30%，超过指导[4] - 第一季度现金流为14亿美元[4] 用户数据 - 生物加工领域订单增长中位数单数字，订单量有所改善[6] - 生物加工领域订单量从上一季度的0.8、0.85增长至本季度的0.95[7] 未来展望 - 预计生物加工库存去库存将在第二季度末结束[8] - 预计中国市场活动水平将保持低水平[11] 新产品和新技术研发 - Aldevron在收购时的营收约为2.5亿美元，目前保持着健康的双位数增长[42] - Aldevron是供应基因编辑市场质粒和其他蛋白质的黄金标准[42] 市场扩张和并购 - Abcam在收购后的前五个月已经开始采取措施整合，并计划成为Danaher OpCo[44] - Danaher计划在2024年实现16亿美元的可持续呼吸测试收入[48] 负面信息 - 预计生物技术领域资金水平有所改善，但对订单率的影响需要两三个季度才能体现[10]

Danaher (DHR) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this industrial and medical device maker have returned -0.4% over the past month versus the Zacks S&P 500 composite's -0.2% change. The Zacks Diversified Operations industry, to which Danaher belongs, has gained 1.6% over this period. Now the key question is: Where could the stock be headed in ...

WASHINGTON, May 7, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Tuesday, May 14, 2024 at 10:40 a.m. PT. The event will be simultaneously webcast on www.danaher.com.ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human h ...